Carboplatin is a platinum-based chemotherapy drug used primarily to treat advanced ovarian cancer. It is one of the most widely prescribed chemotherapy agents in oncology, and while ovarian cancer is its only FDA-approved indication, oncologists routinely use it against several other cancer types, including lung cancer and head and neck cancers.
FDA-Approved Uses
Carboplatin is officially approved for advanced ovarian cancer in two settings. As a first-line treatment, it is given alongside other chemotherapy drugs, most commonly paclitaxel. For ovarian cancer that has come back after earlier chemotherapy, carboplatin can be used on its own as a palliative treatment to slow disease progression and manage symptoms.
Other Cancers Treated With Carboplatin
In clinical practice, carboplatin’s use extends well beyond ovarian cancer. It is a standard component of combination regimens for non-small-cell lung cancer, one of the most common cancers worldwide. It is also used in head and neck squamous cell carcinoma, where it may be paired with paclitaxel and newer immunotherapy drugs. Other cancers commonly treated with carboplatin include bladder cancer, breast cancer (particularly triple-negative subtypes), and certain testicular and endometrial cancers.
These uses are considered “off-label” in the sense that they fall outside the original FDA approval, but they are well supported by clinical trial data and widely accepted in standard oncology guidelines. Your oncologist selects carboplatin based on your specific cancer type, its stage, and how well your kidneys function.
How Carboplatin Works
Carboplatin kills cancer cells by damaging their DNA. Once the drug enters a cell’s nucleus, the platinum atom attaches to specific building blocks of DNA, initially forming a single attachment point called a monoadduct. That first bond then reacts with a second spot on the DNA strand, creating cross-links that lock the two strands together or warp the structure of a single strand. These cross-links prevent the cell from copying its DNA correctly, which blocks cell division and eventually triggers cell death.
Carboplatin is closely related to an older drug, cisplatin. Both create the same type of DNA damage, but carboplatin’s chemical structure makes it slower to bind, which translates to a milder side effect profile, particularly less kidney toxicity and less severe nausea. That tradeoff is the main reason carboplatin has largely replaced cisplatin for many cancer types.
How Treatment Is Given
Carboplatin is delivered as an intravenous infusion, typically at a cancer center or hospital outpatient clinic. When given with paclitaxel, one of the most common pairings, the full appointment lasts about six hours, including pre-medications to prevent allergic reactions and nausea. One cycle repeats every three weeks, and most treatment plans call for six cycles, though the exact number depends on how well the cancer responds.
Unlike many chemotherapy drugs dosed strictly by body size, carboplatin is dosed using a formula called the Calvert formula. It factors in your kidney function (specifically, your glomerular filtration rate) and a target drug exposure level chosen by your oncologist. This approach tailors the dose to how quickly your body can clear the drug, reducing the risk of both underdosing and excessive toxicity.
Common Side Effects
The most significant side effect of carboplatin is bone marrow suppression, meaning it temporarily reduces the production of blood cells. This is the factor that limits how much drug can be given. White blood cell counts, red blood cell counts, and platelet counts all drop, typically reaching their lowest point around day 21 of each cycle. Anemia affects roughly 71% of patients, and in some cases the drop in platelets or red blood cells is severe enough to require a blood transfusion.
Nausea and vomiting are also common, occurring in about 65% of patients. For those who have already received prior chemotherapy, the rate climbs to around 81%. Modern anti-nausea medications given before each infusion help considerably, but breakthrough nausea still happens.
Peripheral neuropathy, a tingling or numbness in the hands and feet, occurs in about 4% of patients receiving carboplatin alone. That rate rises to around 10% in people over 65 or those who previously received cisplatin. Neuropathy is a bigger concern when carboplatin is combined with paclitaxel, since paclitaxel independently causes nerve damage. For patients at higher neuropathy risk, such as those with diabetes, oncologists sometimes substitute docetaxel for paclitaxel in the combination regimen to reduce nerve-related side effects.
Less common but serious side effects include allergic reactions (which can be life-threatening, particularly after multiple cycles), kidney problems, liver changes, and hearing loss or ringing in the ears.
Drug Shortage Concerns
Carboplatin has faced ongoing supply shortages affecting multiple manufacturers. Several companies have reported limited availability due to increased demand, shipping delays, or product discontinuation of certain vial sizes. Some formulations are on back order with estimated release dates stretching into mid-2026. Because no single drug can be directly substituted for carboplatin across all cancer types, shortages can force oncologists to choose alternative regimens based on each patient’s specific situation, kidney and liver function, and tumor type. If you are starting or continuing carboplatin treatment, your care team will verify supply availability before beginning each cycle.